Atlas Trials

TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.

Clinical trial NCT04392479 · UNKNOWN

Trial details

NCT number
NCT04392479
Sponsor
Hôpital Franco-Britannique-Fondation Cognacq-Jay
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
Cancer ColorectalMetastasis
Start date
2020-09-02
Primary completion
2023-06-15
Enrollment
202

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.